Mandate

Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories

Vinge advises Atlas Antibodies AB (majority owned by Patricia Industries, a part of Investor AB), in connection with its acquisition of HistoCyte Laboratories Ltd.

HistoCyte Laboratories’ portfolio of cell line materials provide control of immunohistochemical assays used in the diagnosis of cancer. The company has established a significant presence on important markets such as the UK and USA.

Closing is expected during early March 2021.

Vinge’s team consisted of Jonas Johansson together with Viktor Lennartsson (M&A), Albert Wållgren and Josefine Lanker (Banking and Finance) and Clara Sohlberg (Capital Markets and Public M&A).

Related

Vinge has advised EQT AB in connection with the refinancing of EQT’s EUR 1,500,000,000 sustainability-linked revolving credit facility

The sustainability-linked credit facility has a tenor of 5 years with two 1-year extension options.
July 23, 2024

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.
July 19, 2024

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024